Highlights and interviews from the American Society of Hematology’s Annual Meeting.

Eugenia Vicky Asare, MD: Multidisciplinary Care Saves Lives Among Pregnant Women with SCD in Ghana

Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?

Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma

Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

Crystal Mackall, MD: Passing the Checkpoint With New Approaches to Immunotherapy

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients

Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO

Not Just CRISPR: Changing Biology Through Gene-Editing

Sattva S. Neelapu, MD: Encouraging Results for CAR T-Cells in Refractory DLBCL

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

Robert E. Marcus, MD: GALLIUM Study of Obinutuzumab in Untreated Follicular Lymphoma

John Mascarenhas, MD, MS: Continuing to Evaluate Pacritinib for Myelofibrosis

Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

Dan T. Vogl, MD: Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory” Myeloma Patients

Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL

Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease

Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology

Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?

Multiple Advances in Multiple Myeloma

What Was Hot at ASH 2015?

Rivaroxaban in Cancer-Associated VTE: Results from CALLISTO

Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL

The Balancing Act of Caring for Older Patients with Hemophilia

Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL

Improving Quality of VTE Care

The PROs of Patient-Reported Outcomes

Induction Chemotherapy for AML: Understanding the Patient Experience

Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma

Ixazomib Extends PFS in the TOURMALINE-MM1 Trial

Evolving Issues in Anticoagulation

Predicting Prognosis in Myelodysplastic Syndromes

New Approaches in CLL and Prolymphocytic Leukemia

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia

Optimizing Therapy in Sickle Cell Disease

Controversy over Quality

Eligibility Criteria Not Associated with Adverse Events in RCTs

Newly Approved Drugs: How Should We Use Them in the Clinic?

Guiding Hematologic Care with Genetic Testing

back to top